Torben Frøstrup Hansen

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. MicroRNAs 74%
3. Colonic Neoplasms 68%
4. Neoplasms 38%
5. Drug Therapy 36%
6. Bevacizumab 34%
7. Oxaliplatin 34%
8. Rectal Neoplasms 27%
9. Capecitabine 25%
10. Survival 23%
11. Single Nucleotide Polymorphism 21%
12. Vascular Endothelial Growth Factor A 20%
13. Biomarkers 20%
14. Circulating Tumor DNA 20%
15. Progression-Free Survival 18%
16. Biliary Tract Neoplasms 18%
17. Therapeutics 17%
18. Epidermal Growth Factor 17%
19. Circulating MicroRNA 15%
20. Prostatic Neoplasms 15%
21. Microvessels 15%
22. Panitumumab 13%
23. Confidence Intervals 12%
24. Natural Killer Cells 12%
25. DNA 11%
26. Vascular Endothelial Growth Factor Receptor-2 11%
27. Genes 10%
28. Recurrence 10%
29. Angiogenesis Inhibitors 10%
30. XELOX 10%
31. Immunotherapy 9%
32. Combination Drug Therapy 9%
33. Chemoradiotherapy 9%
34. Denmark 9%
35. Population 8%
36. Microsatellite Instability 8%
37. Mutation 8%
38. Homeobox Genes 8%
39. Disease-Free Survival 8%
40. DNA Mismatch Repair 7%
41. Polymerase Chain Reaction 7%
42. Adenocarcinoma 7%
43. Exons 7%
44. gemcitabine 7%
45. Lung Neoplasms 6%
46. regorafenib 6%
47. In Situ Hybridization 6%
48. pembrolizumab 6%
49. Urokinase Plasminogen Activator Receptors 6%
50. Drug Repositioning 6%